Last reviewed · How we verify
NCT03835091: BRASS-ICU
Use of BRASS in Sedated Critically-ill Patients as a Predictable Mortality Factor
trial testing BRASS score in Brainstem Response in 110 participants. Completed in 26 August 2019.
29 May 2019
Quick facts
| Lead sponsor | CHU de Reims |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 110 |
| Start date | 7 February 2019 |
| Primary completion | 29 May 2019 |
| Estimated completion | 26 August 2019 |
| Sites | 1 location across France |
Drugs / interventions tested
- BRASS score
Conditions studied
- Brainstem Response — all drugs for Brainstem Response →
Sponsor
CHU de Reims — full company profile →
Who can join
18 and older, any sex, with Brainstem Response. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Sedation is used for 30 to 70 % of all intensive care unit (ICU) patients. Deep sedation can be used for lot of disease like acute respiratory distress syndrome, septic shock. Deep sedation was defined by RASS (Richmond Assessment Sedation Scale) below -3. Deep sedation can be associated with increased mortality, length stay, duration of mechanical ventilation, acute brain dysfunction. The french exploration neurologic group in ICU developed a score used Brainstem response patterns in patient deeply sedated by midazolam and showed that a high BRASS score is associated with high mortality at day 28. The investigators think that BRASS score isn't associated with the medication used for sedation. In this study the investigators included all patients sedated independently of medication used for sedation, we also excluded patient with neurologic disorder. The main objective is to shown that high BRASS score at admission of patient without neurologic disorder sedated is predictive of 28-day mortality.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Use of BRASS in sedated critically-ill patients as a predictable mortality factor: BRASS-ICU.
Legros V, Mourvillier B, Floch T, Candelier Q, et al · · 2021 · cited 3× · PMID 33208055 · DOI 10.1080/01616412.2020.1849901
Verify or expand the search:
- PubMed search for NCT03835091
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other CHU de Reims trials
Trials by the same sponsor.
- NCT06955767 — Measurement of MMP-14 Protein, a Potential New Marker for Colorectal Cancer Detection, in Plasma Vesicles Named Exosomes · NA · recruiting
- NCT07163338 — Prevalence and Consequences of Antiphospholipid Syndrome in Patients Aged 65 and Over With Ischemic Strokes (IS) · NA · recruiting
- NCT07274631 — A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine · recruiting
- NCT06782997 — Performance of the Electroretinogram, Performed and Interpreted by an Advanced Practice Nurse, in the Screening for Diab · recruiting
- NCT07016035 — Translation and Validation of the French mPCOSQ (mPCOSQ-F). · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03835091 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by CHU de Reims
- Last refreshed: 23 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03835091.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing